Lubricant Eye Drops Solution/ Drops
NDC 85185-002
Product Information
Lubricant Eye Drops (propylene gycol 0.6%) is a OTC MONOGRAPH DRUG-approved product labeled by Solis Pharmaceuticals Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a solution/ drops for ophthalmic administration. This product entry covers the primary NDC 85185-002 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 85185-002?
What are the uses of this product?
What are Active Ingredients of this product?
- PROPYLENE GLYCOL 6 mg/mL - Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- EDETATE DISODIUM (UNII: 7FLD91C86K)
- BORIC ACID (UNII: R57ZHV85D4)
- CALCIUM CHLORIDE (UNII: M4I0D6VV5M)
- MAGNESIUM CHLORIDE (UNII: 02F3473H9O)
- POTASSIUM CHLORIDE (UNII: 660YQ98I10)
- WATER (UNII: 059QF0KO0R)
- SODIUM BORATE (UNII: 91MBZ8H3QO)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1041798 - propylene glycol 0.6 % Ophthalmic Solution
- RxCUI: 1041798 - propylene glycol 6 MG/ML Ophthalmic Solution
* Please review the full disclaimer at the bottom of this page.